Nanobiotix S.A. (NANO.PA)

3.92 €

+0.04 (+1.03%)
Rating:
Recommendation:
-
Symbol NANO.PA
Price 3.92 €
Beta 1.863
Volume Avg. 0.06M
Market Cap 136.662M
Shares () -
52 Week Range 3.14-380.5
1y Target Est -
DCF Unlevered NANO.PA DCF ->
DCF Levered NANO.PA LDCF ->
ROE -130.33% Strong Sell
ROA -56.77% Strong Sell
Operating Margin -
Debt / Equity 4399.11% Strong Buy
P/E -2.89 Sell
P/B 47.32 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Dr. Laurent Levy
Healthcare
Biotechnology
Paris

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.